In summary, these findings suggest that β‐sitosterol may attenuate the progression and malignancy of HCC by suppressing the activation of the Wnt/β‐catenin signalling pathway via FOXM1 inhibition. Here, FOXM1 is linked to hepatocellular carcinoma.